GAITHERSBURG, Md., Dec. 6, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (the "Company" or "Cytomedix") announced today the formation of a Scientific Advisory Board (SAB) comprised of recognized leaders in wound care and regenerative medicine. The initial six-member SAB, which includes physicians, clinicians and medical researchers, will provide counsel to Cytomedix management on a range of scientific, clinical, product development and commercialization topics.
